BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 21953502)

  • 1. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.
    Azzopardi N; Lecomte T; Ternant D; Boisdron-Celle M; Piller F; Morel A; Gouilleux-Gruart V; Vignault-Desvignes C; Watier H; Gamelin E; Paintaud G
    Clin Cancer Res; 2011 Oct; 17(19):6329-37. PubMed ID: 21953502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
    Van Cutsem E; Tejpar S; Vanbeckevoort D; Peeters M; Humblet Y; Gelderblom H; Vermorken JB; Viret F; Glimelius B; Gallerani E; Hendlisz A; Cats A; Moehler M; Sagaert X; Vlassak S; Schlichting M; Ciardiello F
    J Clin Oncol; 2012 Aug; 30(23):2861-8. PubMed ID: 22753904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer.
    Pointreau Y; Azzopardi N; Ternant D; Calais G; Paintaud G
    Ther Drug Monit; 2016 Oct; 38(5):567-72. PubMed ID: 27631463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.
    Krens LL; Baas JM; Verboom MC; Paintaud G; Desvignes C; Guchelaar HJ; Gelderblom H
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1303-6. PubMed ID: 24705976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody.
    Hasegawa H; Taniguchi H; Mitani S; Masuishi T; Komori A; Narita Y; Kadowaki S; Ura T; Ando M; Yatabe Y; Muro K
    Oncology; 2017; 92(4):205-212. PubMed ID: 28142137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.
    Brulé SY; Jonker DJ; Karapetis CS; O'Callaghan CJ; Moore MJ; Wong R; Tebbutt NC; Underhill C; Yip D; Zalcberg JR; Tu D; Goodwin RA
    Eur J Cancer; 2015 Jul; 51(11):1405-14. PubMed ID: 25979833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
    Azad N; Dasari A; Arcaroli J; Taylor GE; Laheru DA; Carducci MA; McManus M; Quackenbush K; Wright JJ; Hidalgo M; Diaz LA; Donehower RC; Zhao M; Rudek MA; Messersmith WA
    Invest New Drugs; 2013 Apr; 31(2):345-54. PubMed ID: 22615057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors.
    Guo Y; Remaily BC; Thomas J; Kim K; Kulp SK; Mace TA; Ganesan LP; Owen DH; Coss CC; Phelps MA
    Clin Cancer Res; 2024 Mar; 30(5):942-958. PubMed ID: 37921739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients.
    Lobet S; Paintaud G; Azzopardi N; Passot C; Caulet M; Chautard R; Desvignes C; Capitain O; Tougeron D; Lecomte T; Ternant D
    Clin Pharmacokinet; 2023 Sep; 62(9):1263-1274. PubMed ID: 37442917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma.
    Stegelmeier AA; Santry LA; Guilleman MM; Matuszewska K; Minott JA; Yates JGE; Stevens BAY; Thomas SP; Vanderkamp S; Hanada K; Pei Y; Rghei AD; van Vloten JP; Pereira M; Thompson B; Major PP; Petrik JJ; Bridle BW; Wootton SK
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study.
    Marin C; Khoudour N; Millet A; Lebert D; Bros P; Thomas F; Ternant D; Lacarelle B; Guitton J; Ciccolini J; Blanchet B
    Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective.
    Lucas AT; Moody A; Schorzman AN; Zamboni WC
    Antibodies (Basel); 2021 Jul; 10(3):. PubMed ID: 34449544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A plug-and-play platform of ratiometric bioluminescent sensors for homogeneous immunoassays.
    Ni Y; Rosier BJHM; van Aalen EA; Hanckmann ETL; Biewenga L; Pistikou AM; Timmermans B; Vu C; Roos S; Arts R; Li W; de Greef TFA; van Borren MMGJ; van Kuppeveld FJM; Bosch BJ; Merkx M
    Nat Commun; 2021 Jul; 12(1):4586. PubMed ID: 34321486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology.
    Chatelut E; Hendrikx JJMA; Martin J; Ciccolini J; Moes DJAR
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00757. PubMed ID: 33745217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients.
    Shibata K; Naito T; Hirakawa S; Suzuki K; Hosokawa S; Mineta H; Kawakami J
    Cancer Chemother Pharmacol; 2021 Apr; 87(4):555-565. PubMed ID: 33462734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Various Phase I Combination Therapy Designs in Oncology for Evaluation of Early Tumor Shrinkage Using Simulations.
    Seurat J; Girard P; Goteti K; Mentré F
    CPT Pharmacometrics Syst Pharmacol; 2020 Dec; 9(12):686-694. PubMed ID: 33080100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study.
    Grisic AM; Khandelwal A; Bertolino M; Huisinga W; Girard P; Kloft C
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):628-638. PubMed ID: 33015996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer.
    Papachristos A; Kemos P; Kalofonos H; Sivolapenko G
    Oncologist; 2020 Oct; 25(10):853-858. PubMed ID: 32272489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [
    van Helden EJ; Elias SG; Gerritse SL; van Es SC; Boon E; Huisman MC; van Grieken NCT; Dekker H; van Dongen GAMS; Vugts DJ; Boellaard R; van Herpen CML; de Vries EGE; Oyen WJG; Brouwers AH; Verheul HMW; Hoekstra OS; Menke-van der Houven van Oordt CW
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):849-859. PubMed ID: 31705176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology.
    Chatelut E; Le Louedec F; Milano G
    Clin Pharmacokinet; 2020 Mar; 59(3):287-296. PubMed ID: 31701469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.